Skip to search boxSkip to navigationSkip to main content

Clinical factors associated with COVID-19 severity in mexican patients: Cross-sectional analysis from a multicentric hospital study

  • Joel Monárrez-Espino(corresponding author)
    ,
  • Carolina Ivette Zubía-Nevárez
    ,
  • Lorena Reyes-Silva
    ,
  • Juan Pablo Castillo-Palencia
    ,
  • Julio Enrique Castañeda-Delgado
    ,
  • Ana Sofía Herrera Van-Oostdam
*Corresponding author for this work
  • ,
  • Hospital Christus Muguerza Alta Especialidad
    ,
  • Universidad de Monterrey
    ,
  • General Hospital of Soledad de Graciano Sánchez
    ,
  • Instituto Mexicano del Seguro Social
    ,
  • San Luis Potosí Autonomous University
Research Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Publication metrics

Metrics

SciVal
FWCI
0.18
SciVal
Author count
7
SciVal
Paper percentile
32
SciVal
Citations
2
Scopus
Citations

Abstract

(1) Background: Latin America has been harshly hit by SARS-CoV-2, but reporting from this region is still incomplete. This study aimed at identifying and comparing clinical characteristics of patients with COVID-19 at different stages of disease severity. (2) Methods: Cross-sectional multi-centric study. Individuals with nasopharyngeal PCR were categorized into four groups: (1) negative, (2) positive, not hospitalized, (3) positive, hospitalized with/without supplementary oxygen, and (4) positive, intubated. Clinical and laboratory data were compared, using group 1 as the reference. Multivariate multinomial logistic regression was used to compare adjusted odds ratios. (3) Results: Nine variables remained in the model, explaining 76% of the variability. Men had increased odds, from 1.90 (95%CI 0.87–4.15) in the comparison of 2 vs. 1, to 3.66 (1.12–11.9) in 4 vs. 1. Diabetes and obesity were strong predictors. For diabetes, the odds for groups 2, 3, and 4 were 1.56 (0.29–8.16), 12.8 (2.50–65.8), and 16.1 (2.87–90.2); for obesity, these were 0.79 (0.31–2.05), 3.38 (1.04–10.9), and 4.10 (1.16–14.4), respectively. Fever, myalgia/arthralgia, cough, dyspnea, and neutrophilia were associated with the more severe COVID-19 group. Anosmia/dysgeusia were more likely to occur in group 2 (25.5; 2.51–259). (4) Conclusion: The results point to relevant differences in clinical and laboratory features of COVID-19 by level of severity that can be used in medical practice.

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Article number

895

Journal (Volume, Issue Number)

Healthcare (Switzerland) (Volume 9, Issue 7)

Publication milestones

  • Published - 07/2021

Publication status

Published - 07/2021

ISSN

2227-9032

Publication IDs

  • Scopus: 85111560210

Funding Details

Funding: Funding was received from the Mexican Council of Science and Technology (Grant ID: 311880). Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics and Research Committees of the hospitals involved (CEI-HCMP-15042020-3, R-2020-785-068, and CEI-003-20161034), and funded by the Mexican National Council for Science and Technology under the 2020-1 COVID-19 Contingency call (Grant No. 311880).
FundersFunding numbers
CONACYT
311880